Published in Malar J on March 16, 2011
Identification of Novel Pre-Erythrocytic Malaria Antigen Candidates for Combination Vaccines with Circumsporozoite Protein. PLoS One (2016) 1.39
Pre-erythrocytic malaria vaccines: identifying the targets. Expert Rev Vaccines (2012) 1.07
Identification of non-CSP antigens bearing CD8 epitopes in mice immunized with irradiated sporozoites. Vaccine (2011) 0.92
Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates. Sci Rep (2015) 0.92
The survival of memory CD8 T cells that is mediated by IL-15 correlates with sustained protection against malaria. J Immunol (2013) 0.86
Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine Development. PLoS One (2015) 0.82
The case for a rational genome-based vaccine against malaria. Front Microbiol (2015) 0.81
HLA class II (DR0401) molecules induce Foxp3+ regulatory T cell suppression of B cells in Plasmodium yoelii strain 17XNL malaria. Infect Immun (2013) 0.81
Progress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity". Vaccine (2015) 0.79
Fusion of antigen to a dendritic cell targeting chemokine combined with adjuvant yields a malaria DNA vaccine with enhanced protective capabilities. PLoS One (2014) 0.78
Assessment of the Plasmodium falciparum pre-erythrocytic antigen UIS3 as a potential candidate for a malaria vaccine. Infect Immun (2016) 0.75
Advances in genetics and genomics: use and limitations in achieving malaria elimination goals. Pathog Glob Health (2015) 0.75
Profiling the Targets of Protective CD8(+) T Cell Responses to Infection. Mol Ther Methods Clin Dev (2017) 0.75
A proteomic view of the Plasmodium falciparum life cycle. Nature (2002) 10.65
Discovery of gene function by expression profiling of the malaria parasite life cycle. Science (2003) 10.57
Direct gene transfer into mouse muscle in vivo. Science (1990) 10.39
A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med (1997) 8.22
Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis (2002) 5.43
A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis (2002) 4.14
Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques (1997) 3.74
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One (2009) 2.79
Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. J Exp Med (1996) 2.15
Spread and evolution of Plasmodium falciparum drug resistance. Parasitol Int (2009) 2.11
Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells. J Infect Dis (2007) 1.99
Characterization of Plasmodium yoelii monoclonal antibodies directed against stage-specific sporozoite antigens. Infect Immun (1987) 1.87
Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J Virol (1989) 1.84
Infectivity-associated changes in the transcriptional repertoire of the malaria parasite sporozoite stage. J Biol Chem (2002) 1.83
Differential transcriptome profiling identifies Plasmodium genes encoding pre-erythrocytic stage-specific proteins. Mol Microbiol (2004) 1.76
etramps, a new Plasmodium falciparum gene family coding for developmentally regulated and highly charged membrane proteins located at the parasite-host cell interface. Mol Biol Cell (2003) 1.65
The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immunol (2009) 1.63
Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Hum Vaccin (2010) 1.50
L-FABP is a critical host factor for successful malaria liver stage development. Int J Parasitol (2007) 1.48
Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus. J Immunol (2000) 1.32
Vaccinia virus as an expression vector. Methods Enzymol (1987) 1.25
Plasmodium falciparum infection and exoerythrocytic development in mice with chimeric human livers. Int J Parasitol (2006) 1.24
Transcriptional analysis of in vivo Plasmodium yoelii liver stage gene expression. Mol Biochem Parasitol (2005) 1.22
Reduced immunogenicity of DNA vaccine plasmids in mixtures. Gene Ther (2004) 1.16
Falstatin, a cysteine protease inhibitor of Plasmodium falciparum, facilitates erythrocyte invasion. PLoS Pathog (2006) 1.15
Interaction of an atypical Plasmodium falciparum ETRAMP with human apolipoproteins. Malar J (2008) 1.09
The wheat germ cell-free protein synthesis system: a key tool for novel malaria vaccine candidate discovery. Acta Trop (2009) 1.09
High-throughput generation of P. falciparum functional molecules by recombinational cloning. Genome Res (2004) 1.07
Exoerythrocytic Plasmodium parasites secrete a cysteine protease inhibitor involved in sporozoite invasion and capable of blocking cell death of host hepatocytes. PLoS Pathog (2010) 1.07
Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens. PLoS One (2007) 1.06
Effect on antibody and T-cell responses of mixing five GMP-produced DNA plasmids and administration with plasmid expressing GM-CSF. Genes Immun (2004) 0.92
Assessment and improvement of the Plasmodium yoelii yoelii genome annotation through comparative analysis. Bioinformatics (2008) 0.90
Genome sequence and comparative analysis of the model rodent malaria parasite Plasmodium yoelii yoelii. Nature (2002) 8.92
Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis (2002) 5.43
Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science (2013) 4.60
Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin (2010) 2.36
Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J Infect Dis (2007) 1.94
DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One (2013) 1.47
Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One (2011) 1.32
Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS One (2011) 1.25
Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. Vaccine (2004) 1.24
Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. Hum Gene Ther (2002) 1.21
Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen. Infect Immun (2002) 1.07
Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens. PLoS One (2007) 1.06
Measuring naturally acquired immune responses to candidate malaria vaccine antigens in Ghanaian adults. Malar J (2011) 1.03
Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies. PLoS One (2009) 1.01
Pancreatic islet transplantation using the nonhuman primate (rhesus) model predicts that the portal vein is superior to the celiac artery as the islet infusion site. Diabetes (2002) 0.96
Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein. Malar J (2010) 0.96
Novel antigen identification method for discovery of protective malaria antigens by rapid testing of DNA vaccines encoding exons from the parasite genome. Infect Immun (2004) 0.96
Extended immunization intervals enhance the immunogenicity and protective efficacy of plasmid DNA vaccines. Microbes Infect (2007) 0.96
Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP). Malar J (2013) 0.95
Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA. Hum Vaccin Immunother (2012) 0.95
Anti-sporozoite antibodies as alternative markers for malaria transmission intensity estimation. Malar J (2014) 0.92
Hematopoietic stem cell transplantation prevents diabetes in NOD mice but does not contribute to significant islet cell regeneration once disease is established. Exp Hematol (2005) 0.90
A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates. PLoS One (2013) 0.87
Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines. Immunol Lett (2007) 0.85
Plasmodium: mammalian codon optimization of malaria plasmid DNA vaccines enhances antibody responses but not T cell responses nor protective immunity. Exp Parasitol (2009) 0.85
Histopathological study of intrahepatic islets transplanted in the nonhuman primate model using edmonton protocol immunosuppression. J Clin Endocrinol Metab (2002) 0.85
Induction of diabetes in nonhuman primates by means of temporary arterial embolization and selective arterial injection of streptozotocin. Radiology (2004) 0.85
Unambiguous synthesis and prophylactic antimalarial activities of imidazolidinedione derivatives. J Med Chem (2005) 0.83
Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines. Vaccine (2005) 0.80
Measuring naturally acquired ex vivo IFN-γ responses to Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (CelTOS) in Ghanaian adults. Malar J (2015) 0.80
Reduced production of RNA transcripts from individual DNA plasmids given in a multivalent DNA vaccine formula. Hum Vaccin (2007) 0.79
A glycosylphosphatidylinositol anchor signal sequence enhances the immunogenicity of a DNA vaccine encoding Plasmodium falciparum sexual-stage antigen, Pfs230. Vaccine (2003) 0.79
A small peptide (CEL-1000) derived from the beta-chain of the human major histocompatibility complex class II molecule induces complete protection against malaria in an antigen-independent manner. Antimicrob Agents Chemother (2004) 0.76
Correction: Vaccine Strain-Specificity of Protective HLA-Restricted Class 1 P. falciparum Epitopes. PLoS One (2016) 0.75
Plasmodium falciparum. Mechanisms of innate and acquired protection against Plasmodium falciparum in Javanese transmigrant adults and children newly resident in malaria-endemic Northwest Papua. Adv Exp Med Biol (2003) 0.75